IL129382A - Method for identifying embryonic cells using antibodies against fetal hemoglobin - Google Patents
Method for identifying embryonic cells using antibodies against fetal hemoglobinInfo
- Publication number
- IL129382A IL129382A IL12938297A IL12938297A IL129382A IL 129382 A IL129382 A IL 129382A IL 12938297 A IL12938297 A IL 12938297A IL 12938297 A IL12938297 A IL 12938297A IL 129382 A IL129382 A IL 129382A
- Authority
- IL
- Israel
- Prior art keywords
- fetal
- antibody
- cells
- hemoglobin
- cell
- Prior art date
Links
- 230000001605 fetal effect Effects 0.000 title claims abstract description 140
- 238000000034 method Methods 0.000 title claims abstract description 87
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 45
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 45
- 230000003135 anti-embryonic effect Effects 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 123
- 210000004369 blood Anatomy 0.000 claims abstract description 51
- 239000008280 blood Substances 0.000 claims abstract description 51
- 210000003924 normoblast Anatomy 0.000 claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 21
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 7
- 108091005461 Nucleic proteins Proteins 0.000 claims abstract description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 71
- 239000000523 sample Substances 0.000 claims description 71
- 230000008774 maternal effect Effects 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 18
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 14
- 239000002853 nucleic acid probe Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 102100030826 Hemoglobin subunit epsilon Human genes 0.000 claims description 9
- 108091005879 Hemoglobin subunit epsilon Proteins 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 239000003298 DNA probe Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 230000002175 menstrual effect Effects 0.000 claims description 7
- 108020003215 DNA Probes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 238000010261 blood fractionation Methods 0.000 claims description 3
- 239000002771 cell marker Substances 0.000 claims description 3
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 claims description 2
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 108020004518 RNA Probes Proteins 0.000 claims 1
- 239000003391 RNA probe Substances 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 23
- 230000003321 amplification Effects 0.000 abstract description 13
- 210000003754 fetus Anatomy 0.000 abstract description 13
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 13
- 230000005856 abnormality Effects 0.000 abstract description 5
- 230000002759 chromosomal effect Effects 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 46
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 210000000349 chromosome Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 210000000265 leukocyte Anatomy 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 230000008588 hemolysis Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 239000000084 colloidal system Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000834 fixative Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 238000012252 genetic analysis Methods 0.000 description 5
- 102000018146 globin Human genes 0.000 description 5
- 108060003196 globin Proteins 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 5
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 206010044688 Trisomy 21 Diseases 0.000 description 4
- 238000002669 amniocentesis Methods 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003793 prenatal diagnosis Methods 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- -1 haptens Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000037280 Trisomy Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100030387 Hemoglobin subunit zeta Human genes 0.000 description 1
- 108091005905 Hemoglobin subunit zeta Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010076830 Thionins Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 101150015424 dmd gene Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010022155 hemoglobin Portland Proteins 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14569197A IL145691A (en) | 1996-10-21 | 1997-10-20 | Method to identify fetal cells using anti-embryonic hemoglobin antibodies |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/734,556 US5731156A (en) | 1996-10-21 | 1996-10-21 | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
| PCT/US1997/019447 WO1998018005A1 (en) | 1996-10-21 | 1997-10-20 | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL129382A0 IL129382A0 (en) | 2000-02-17 |
| IL129382A true IL129382A (en) | 2002-09-12 |
Family
ID=24952172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12938297A IL129382A (en) | 1996-10-21 | 1997-10-20 | Method for identifying embryonic cells using antibodies against fetal hemoglobin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5731156A (de) |
| EP (1) | EP1007965B1 (de) |
| JP (1) | JP4091123B2 (de) |
| KR (1) | KR100523381B1 (de) |
| CN (1) | CN1234117A (de) |
| AT (1) | ATE290210T1 (de) |
| AU (1) | AU735380B2 (de) |
| BR (1) | BR9712548A (de) |
| CA (1) | CA2269327A1 (de) |
| DE (1) | DE69732662T2 (de) |
| HK (1) | HK1031255A1 (de) |
| IL (1) | IL129382A (de) |
| RU (1) | RU2178703C2 (de) |
| WO (1) | WO1998018005A1 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6509192B1 (en) * | 1992-02-24 | 2003-01-21 | Coulter International Corp. | Quality control method |
| US5629147A (en) * | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| US6718053B1 (en) * | 1996-11-27 | 2004-04-06 | Chromavision Medical Systems, Inc. | Method and apparatus for automated image analysis of biological specimens |
| JP2000501184A (ja) * | 1995-11-30 | 2000-02-02 | クロマビジョン メディカル システムズ，インコーポレイテッド | 生体標本の自動画像分析の方法および装置 |
| EP0974056B1 (de) * | 1997-03-08 | 2005-11-02 | The University of Dundee | Pränatale diagnostische verfahren in vitro |
| US5962234A (en) * | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
| CN1702459A (zh) * | 1998-05-09 | 2005-11-30 | 伊康尼西斯公司 | 用于包括胎儿细胞的计算机所控制的稀少细胞的基于诊断的方法和装置 |
| FR2781055B1 (fr) * | 1998-07-09 | 2000-10-13 | Immunotech Sa | Reactif et methode pour la permeabilisation et l'identification des erythrocytes |
| WO2000071987A2 (en) * | 1999-05-25 | 2000-11-30 | John Philip | Isolation and culturing of fetal cells |
| US6692952B1 (en) * | 1999-11-10 | 2004-02-17 | Massachusetts Institute Of Technology | Cell analysis and sorting apparatus for manipulation of cells |
| DE10035433C2 (de) * | 2000-07-20 | 2002-07-18 | Tuma Wolfgang | Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben |
| AU2002357588B2 (en) * | 2001-12-11 | 2008-11-20 | Netech Inc. | Blood cell separation system |
| JP2006501449A (ja) | 2002-09-27 | 2006-01-12 | ザ ジェネラル ホスピタル コーポレーション | 細胞分離のためのマイクロ流体デバイスおよびその使用 |
| AU2003254755B2 (en) | 2002-10-16 | 2007-12-20 | Streck, Inc. | Method and device for collecting and preserving cells for analysis |
| US20040214243A1 (en) * | 2003-04-25 | 2004-10-28 | Beckman Coulter, Inc. | Differential determination of hemoglobins |
| US20070160503A1 (en) * | 2003-06-13 | 2007-07-12 | Palaniappan Sethu | Microfluidic systems for size based removal of red blood cells and platelets from blood |
| EP1776449A4 (de) * | 2004-03-03 | 2009-08-12 | Gen Hospital Corp | Magnetvorrichtung zur isolierung von zellen und biomolekülen in einer mikrofluidischen umgebung |
| US7653260B2 (en) * | 2004-06-17 | 2010-01-26 | Carl Zeis MicroImaging GmbH | System and method of registering field of view |
| US8582924B2 (en) * | 2004-06-30 | 2013-11-12 | Carl Zeiss Microimaging Gmbh | Data structure of an image storage and retrieval system |
| US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
| US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20090181421A1 (en) * | 2005-07-29 | 2009-07-16 | Ravi Kapur | Diagnosis of fetal abnormalities using nucleated red blood cells |
| US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
| US20070059716A1 (en) * | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
| US20070059719A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Business methods for prenatal Diagnosis |
| US20070059718A1 (en) * | 2005-09-15 | 2007-03-15 | Mehmet Toner | Systems and methods for enrichment of analytes |
| US20070059781A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
| US20070059774A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
| US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
| WO2008143849A2 (en) * | 2007-05-14 | 2008-11-27 | Historx, Inc. | Compartment segregation by pixel characterization using image data clustering |
| WO2008156669A1 (en) * | 2007-06-15 | 2008-12-24 | Historx, Inc. | Method and system for standardizing microscope instruments |
| CA2604317C (en) | 2007-08-06 | 2017-02-28 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
| CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
| WO2009029810A1 (en) * | 2007-08-31 | 2009-03-05 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
| WO2009085745A1 (en) * | 2007-12-20 | 2009-07-09 | Cytyc Corporation | Method for magnetic separation of red blood cells from a patient sample |
| EP2250497B1 (de) * | 2008-02-18 | 2014-09-10 | Genetic Technologies Limited | Zellprozessierungs- und/oder -anreicherungsverfahren |
| WO2010012002A1 (en) * | 2008-07-25 | 2010-01-28 | Saryna Medical Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
| EP2335221B8 (de) * | 2008-09-16 | 2016-05-25 | Novartis AG | Reproduzierbare quantifizierung einer biomarkerexpression |
| US20100167271A1 (en) * | 2008-12-30 | 2010-07-01 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
| US11634747B2 (en) * | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| US20100304978A1 (en) * | 2009-01-26 | 2010-12-02 | David Xingfei Deng | Methods and compositions for identifying a fetal cell |
| US8231007B2 (en) * | 2009-01-29 | 2012-07-31 | Wark Rickey E | Static classifier cage |
| DK2398912T3 (en) | 2009-02-18 | 2017-10-30 | Streck Inc | Conservation of cell-free nucleic acids |
| AU2010239131A1 (en) * | 2009-04-21 | 2011-11-17 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
| CN102483406A (zh) * | 2009-06-24 | 2012-05-30 | 健康公司-拉姆巴姆 | 用于分离胎盘来源微粒的方法和试剂盒以及它们用于诊断胎儿疾病的应用 |
| EP3103883A1 (de) * | 2009-11-09 | 2016-12-14 | Streck, Inc. | Stabilisierung von rna in und extraktion aus intakten zellen in einer blutprobe |
| CN102762712A (zh) | 2010-01-21 | 2012-10-31 | 百赛普有限公司 | 稀有细胞的磁性分离 |
| US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
| JP5822913B2 (ja) * | 2010-04-20 | 2015-11-25 | ヴェンタナ メディカル システムズ， インク． | ２色発色性インサイツハイブリダイゼーション |
| WO2012151391A2 (en) | 2011-05-04 | 2012-11-08 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| ES2676556T3 (es) * | 2011-12-23 | 2018-07-20 | Depuy Synthes Products Llc | Detección de células derivadas de tejido del cordón umbilical humano |
| CN104508122A (zh) * | 2012-06-20 | 2015-04-08 | 赛璐拉有限公司 | 用于处理细胞群体的材料和方法 |
| EP4008270A1 (de) | 2012-06-22 | 2022-06-08 | Preprogen LLC | Verfahren zur gewinnung fötaler zellen und fötaler zellkomponenten |
| SG10202110062SA (en) * | 2012-11-27 | 2021-11-29 | Childrens Medical Center | Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction |
| CA2907504C (en) * | 2013-03-27 | 2023-01-17 | Theranos, Inc. | Methods, devices, and systems for sample analysis |
| EP3024323B1 (de) | 2013-07-24 | 2022-10-19 | Streck, Inc. | Zusammensetzungen und verfahren zur stabilisierung zirkulierender tumorzellen |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| CN104977284B (zh) * | 2015-07-03 | 2018-05-29 | 石莹 | 一种胎儿有核红细胞的捕获及鉴定方法 |
| KR101794218B1 (ko) * | 2015-08-19 | 2017-11-07 | 인제대학교 산학협력단 | 비침습적 산전 진단을 위한 산모 혈액 내 유핵 적혈구의 농축 분리 방법 |
| WO2017057076A1 (ja) * | 2015-09-28 | 2017-04-06 | 富士フイルム株式会社 | 有核赤血球の取得方法および有核赤血球の識別方法 |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
| JP6234542B1 (ja) | 2016-12-27 | 2017-11-22 | 株式会社 ＴＬ Ｇｅｎｏｍｉｃｓ | 胎児細胞由来染色体ｄｎａの取得方法 |
| US11666915B2 (en) | 2017-10-19 | 2023-06-06 | Tl Genomics Inc. | Cell classification chip |
| CN109115584A (zh) * | 2018-09-10 | 2019-01-01 | 首都医科大学附属北京妇产医院 | 一种检测红细胞中血红蛋白f的检测试剂及其应用 |
| WO2021009682A1 (en) * | 2019-07-15 | 2021-01-21 | Menarini Biomarkers Singapore Pte Ltd | Compositions and methods for isolating, detecting, and analyzing fetal cells |
| CN111948404B (zh) * | 2020-08-03 | 2023-04-07 | 融智生物科技（青岛）有限公司 | 用于筛查地中海贫血的特征蛋白标记组合物、质谱模型及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU658132B2 (en) * | 1989-11-13 | 1995-04-06 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
| BR9306867A (pt) * | 1992-07-17 | 1998-12-08 | Aprogenex Inc | Enriquecimento e identificação de células fetais do sangue materno para a hibridização in situ |
| US5457024A (en) * | 1993-01-22 | 1995-10-10 | Aprogenex, Inc. | Isolation of fetal erythrocytes |
| WO1995003431A1 (en) * | 1993-07-19 | 1995-02-02 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| US5580724A (en) * | 1994-03-25 | 1996-12-03 | Board Of Regents, The University Of Texas System | Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis |
-
1996
- 1996-10-21 US US08/734,556 patent/US5731156A/en not_active Expired - Lifetime
-
1997
- 1997-10-20 CA CA002269327A patent/CA2269327A1/en not_active Abandoned
- 1997-10-20 WO PCT/US1997/019447 patent/WO1998018005A1/en active IP Right Grant
- 1997-10-20 AT AT97911938T patent/ATE290210T1/de not_active IP Right Cessation
- 1997-10-20 IL IL12938297A patent/IL129382A/en not_active IP Right Cessation
- 1997-10-20 DE DE69732662T patent/DE69732662T2/de not_active Expired - Fee Related
- 1997-10-20 RU RU99110373/14A patent/RU2178703C2/ru not_active IP Right Cessation
- 1997-10-20 BR BR9712548-2A patent/BR9712548A/pt not_active Application Discontinuation
- 1997-10-20 EP EP97911938A patent/EP1007965B1/de not_active Expired - Lifetime
- 1997-10-20 CN CN97199005A patent/CN1234117A/zh active Pending
- 1997-10-20 JP JP51969498A patent/JP4091123B2/ja not_active Expired - Fee Related
- 1997-10-20 KR KR10-1999-7003439A patent/KR100523381B1/ko not_active IP Right Cessation
- 1997-10-20 AU AU49200/97A patent/AU735380B2/en not_active Ceased
-
2000
- 2000-12-14 HK HK00108086A patent/HK1031255A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU735380B2 (en) | 2001-07-05 |
| CA2269327A1 (en) | 1998-04-30 |
| JP2001502805A (ja) | 2001-02-27 |
| IL129382A0 (en) | 2000-02-17 |
| WO1998018005A1 (en) | 1998-04-30 |
| EP1007965B1 (de) | 2005-03-02 |
| AU4920097A (en) | 1998-05-15 |
| EP1007965A1 (de) | 2000-06-14 |
| KR20000052662A (ko) | 2000-08-25 |
| DE69732662D1 (de) | 2005-04-07 |
| CN1234117A (zh) | 1999-11-03 |
| BR9712548A (pt) | 1999-12-21 |
| DE69732662T2 (de) | 2005-12-29 |
| EP1007965A4 (de) | 2000-06-14 |
| ATE290210T1 (de) | 2005-03-15 |
| US5731156A (en) | 1998-03-24 |
| HK1031255A1 (en) | 2001-06-08 |
| RU2178703C2 (ru) | 2002-01-27 |
| JP4091123B2 (ja) | 2008-05-28 |
| KR100523381B1 (ko) | 2005-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU735380B2 (en) | Use of anti-embryonic hemoglobin antibodies to identify fetal cells | |
| US5962234A (en) | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells | |
| CA2140278C (en) | Enriching and identyfing fetal cells in maternal blood for in situ hybridization | |
| US5714325A (en) | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood | |
| US5153117A (en) | Fetal cell recovery method | |
| EP0500727B1 (de) | Ein nichtinvasives verfahren zur trennung und zum nachweis von fetaler dna | |
| US6210889B1 (en) | Method for enrichment of fetal cells from maternal blood and use of same in determination of fetal sex and detection of chromosomal abnormalities | |
| US5861311A (en) | Preserved, non-infectious control cells prepared by the modulation or modification of normal leukocytes | |
| Davis et al. | Use of monoclonal antibodies and flow cytometry to cluster and analyze leukocyte differentiation molecules | |
| JPH09510875A (ja) | 母親の末梢血からの胎児細胞の培養および単離 | |
| WO1994025873A1 (en) | Methods for enriching fetal progenitor cells from maternal blood | |
| EP0660664B1 (de) | Konservierte nicht-infektiöse markerzellen zur verwendung in der feststellung einer krankheit durch eine blutuntersuchung | |
| Christensen et al. | Studies on the isolation and identification of fetal nucleated red blood cells in the circulation of pregnant women before and after chorion villus sampling | |
| US5763204A (en) | Preparation of preserved, non-infectious control cell for use in the identification of a disease through blood testing | |
| MXPA99003697A (en) | Use of anti-embryonic hemoglobin antibodies to identify fetal cells | |
| US4693967A (en) | Monitoring therapy results in body samples of receptor cells | |
| Bischoff et al. | Prenatal Diagnosis of Chromosomal Abnormalities Using Maternal Blood | |
| AU9718698A (en) | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood | |
| AU7735201A (en) | Fetal cell recovery method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |